NIH gives med tech company $1.9M to improve deep brain stimulation for Parkinson's

The NIH funded GreatLakes NeuroTechnologies' deep brain stimulator for Parkinson's disease to the tune of $1.9 million. The money will go towards studying methods of programming the device to maximize efficacy and minimize the amount of time clinicians spend optimizing settings. "We demonstrated in two studies that intelligent algorithms using sensor feedback could successfully identify optimal stimulation parameters that significantly improved motor symptoms or maintained therapeutic benefits while reducing stimulation amplitude by an average of 50% to decrease battery usage," said Dustin Heldman, the company's biomedical research manager. "One previous limitation was separate systems were used for assessment and programming. We look forward to this next phase, which will directly integrate the systems to improve clinical workflow and speed programming time." More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.